CHINOOK Asthma Study

STUDY BASICS

Do you have severe eosinophilic asthma? Are you 18-65 years old? If so, you may be able to take part in a research study to learn more about how an FDA-approved medication called benralizumab (Fasenra®) works for the treatment of asthma patients who have persistent symptoms despite using controller medications. Compensation is provided.

STUDY PURPOSE

Eosinophilic asthma—a type of asthma due to inflammation in the lungs caused by white blood cells called eosinophils—is often severe and difficult to treat. Many people who have severe eosinophilic asthma require the frequent use of a rescue inhaler, wake up at night due to asthma symptoms, take oral steroids, and have asthma attacks that require emergency care.

Benralizumab (also known by the brand name Fasenra®) is FDA-approved for the treatment of severe eosinophilic asthma, but researchers want to better understand the effects of benralizumab. The purpose of this study is to learn more about how benralizumab works to control asthma in people with severe eosinophilic asthma.

COULD THIS STUDY BE RIGHT FOR YOU?

• Ages 18-65
• Diagnosed by a physician with severe eosinophilic asthma
• Non-smoker or tobacco-free for at least one year (former smokers must not have a smoking history greater than 15 pack-years: pack-year calculator: https://www.smokingpackyears.com/)
• Not pregnant

WHAT PARTICIPANTS CAN EXPECT

Participation involves about 13 in-person visits over 58 weeks. Most visits will last about 3-4 hours. During an initial 6-week screening period, participants will have 2 visits to make sure they are eligible to take part in the study.

Eligible participants will begin the 48-week treatment phase of the study that includes 10 visits. Participants will be randomly assigned (like the flip of a coin) to receive either benralizumab or placebo by subcutaneous injection (under the skin). The placebo looks like benralizumab but contains no medication. Following the treatment period, participants will be followed for 4 weeks and have one final visit.

Tests and assessments during the study include physical exams, questionnaires, electrocardiogram, blood draws, sputum collection, lung function tests, bronchoscopy, and CT scans.

Participants will receive compensation per completed study visit for their participation in this study.